SHC Stock Analysis — Sotera Health Company
Sector: Healthcare
AI Verdict
SHC is cheap for the growth you're getting if the earnings surge materializes, but you're paying up for a narrative that hinges entirely on a massive rebound.
Competitive Moat
Sotera Health provides essential sterilization and lab testing services for the medical device and pharmaceutical industries, where regulatory requirements create high switching costs. Its entrenched relationships with major healthcare manufacturers and stringent compliance standards make its service contracts sticky and defensible.
Summary
SHC is on watch because analysts expect a 248.9% jump in earnings next year, slashing its forward P/E to 16.0x.
Where It Stands
SHC trades at 16.0x next year's earnings, well below the healthcare sector median of 22x, while trailing P/E is 55.9x due to depressed earnings that are expected to rebound sharply.
Key Metrics
- Trailing P/E: 55.9x
- Forward P/E: 16.0x
- PEG Ratio: 0.22
- Earnings Growth: +2.5%
- Revenue Growth: +0.1%
- 52-Week High: $19.85
- 52-Week Low: $10.79
Analyst Consensus
12 Buy · 3 Hold · 0 Sell (15 analysts)
Bull Case
With forward EPS growth forecast at 248.9%, the current 16.0x forward P/E looks cheap for the explosive rebound analysts are betting on.
Bear Case
If the earnings rebound doesn't materialize, the trailing P/E of 55.9x leaves plenty of room for the stock to fall back toward sector norms, risking a steep multiple compression.
Catalyst to Watch
Watch for quarterly earnings reports—any sign that EPS growth falls short of the 248.9% target could quickly unwind the low forward P/E narrative.